Press Releases

07 October 2026

Byondis to Profile Potential of Platform Technologies at World ADC San Diego, Advancing Strategy to Lead the Antibody-Drug Conjugate Field

18 May 2026

Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development

17 April 2026

Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026

09 April 2026

Byondis Appoints Christoph Korpus, PhD, MBA as Chief Executive Officer

11 December 2025

Byondis Announces Strategic Transformation to Deliver Next Generation Antibody-Drug Conjugate Technology Platforms & Focus on Partnering

03 June 2025

Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients with Advanced or Metastatic Solid Tumors

24 March 2025

Byondis Appoints Christoph Korpus, PhD, MBA, as Chief Business Officer

19 November 2024

Byondis Appoints Louis Denis, M.D., as Chief Medical Officer

21 September 2024

Byondis contributed to an international white paper on Reference Standards for Potency Assays

30 June 2024

Oral presentation at the ECB, European Congress on Biotechnology, on Cell Tolerant Affinity Chromatography

25 April 2024

Oral presentation at the Oxford Global Immuno 2024 congress

08 April 2024

Poster presentation at AACR Annual Meeting 2024: BYON4413

15 May 2023

U.S. Food and Drug Administration Issues Complete Response Letter for Byondis’ [Vic-]Trastuzumab Duocarmazine

17 April 2023

Preclinical Characterization of Anti-SIRPα mAb BYON4228 Published in Journal for ImmunoTherapy of Cancer

12 April 2023

Preclinical Data on the Potential of Byondis ADC BYON3521 Published in Molecular Cancer Therapeutics

16 September 2022

Byondis Campus Officially Opened

25 August 2022

Byondis Initiates Phase I Study of Next Generation Antibody-Drug Conjugate BYON3521

18 July 2022

EMA Validates Marketing Authorization Application for Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer

12 July 2022

FDA Accepts Byondis’ Biologics License Application for [Vic-]Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer

03 May 2022

Byondis and medac Enter Into License and Collaboration and Supply Agreements for Anti-HER2 ADC Trastuzumab Duocarmazine (SYD985)

11 October 2021

Byondis Lights Up Research Building for Metastatic Breast Cancer Awareness Day

07 October 2021

Byondis World ADC Highlights

19 September 2021

Byondis ESMO Late-Breaking Presentation Confirms ADC [Vic-] Trastuzumab Duocarmazine (SYD985) Superior to Physician’s Choice in Pre-treated Locally Advanced or Metastatic HER2-Positive Breast Cancer

27 July 2021

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets

15 July 2021

Byondis Appoints Timo van den Berg as Senior Director, Immuno-Oncology R&D

08 June 2021

Byondis Announces Positive Topline Results of Pivotal Phase III TULIP® Study in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

11 January 2021

Byondis to Present at J.P. Morgan Healthcare Conference

12 November 2020

Byondis to Present at the Jefferies 2020 Virtual Healthcare Conference

28 September 2020

Byondis Announces Appointment of New Vice President, Intellectual Property

25 August 2020

Byondis Initiates Phase I Study of ADC [Vic-]Trastuzumab Duocarmazine + Niraparib in HER2-Expressing Solid Tumors

19 August 2020

Byondis Announces Appointment of Chief Financial Officer

11 August 2020

Byondis Initiates Phase I Study of Antibody-Drug Conjugate SYD1875

15 July 2020

Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer

07 July 2020

Byondis’ Investigational Antibody-Drug Conjugate SYD985 Selected for I-SPY 2 TRIAL™ in Early-Stage Breast Cancer

30 April 2020

Byondis’ Annual Molecular Sciences Scholarship at Radboud University is Underway

16 April 2020

Synthon Biopharmaceuticals rebranded as Byondis

07 October 2026

18 May 2026

17 April 2026

09 April 2026

11 December 2025

03 June 2025

24 March 2025

19 November 2024

21 September 2024

30 June 2024

25 April 2024

08 April 2024

15 May 2023

17 April 2023

12 April 2023

16 September 2022

25 August 2022

18 July 2022

12 July 2022

03 May 2022

11 October 2021

07 October 2021

19 September 2021

27 July 2021

15 July 2021

08 June 2021

11 January 2021

12 November 2020

28 September 2020

25 August 2020

19 August 2020

11 August 2020

15 July 2020

07 July 2020

30 April 2020

16 April 2020

Partnering

Investors & Media

You are leaving Byondis.com